Walleye Capital
BBOT

Walleye Capital’s BridgeBio Oncology BBOT Stock Holding History

Walleye Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-92,864
Closed -$949K – 5961
2024
Q2 		$949K Buy
92,864
+640
+0.7% +$6.59K ﹤0.01% 2907
2024
Q1 		$955K Buy
+92,224
New +$955K ﹤0.01% 2635

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Walleye Capital's BBOT Position: Q3 2024 in Review

Walleye Capital sold out of BridgeBio Oncology (BBOT) in Q3 2024, closing a stake of 92,864 shares — an estimated $949K sold.

Walleye Capital first reported a position in BBOT in Q1 2024 and held it in 2 quarters. The position peaked at $955K in Q1 2024. 31 funds tracked by Wall St. Rank hold BBOT as of Q3 2024.

  • Walleye Capital reported no remaining BridgeBio Oncology position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 92,864 BridgeBio Oncology shares in Q3 2024, an estimated $949K.
  • Walleye Capital first reported a position in BridgeBio Oncology in Q1 2024 and held it in 2 quarters.
  • Walleye Capital's BridgeBio Oncology position peaked at $955K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.